Insulin sensitizers in polycystic ovary syndrome.

From the conceptual point of view, there are several reasons to expect that improvement of insulin sensitivity may produce several benefits in the treatment of a complex disorder like polycystic ovary syndrome (PCOS), including a decrease in insulin and androgen levels, improvement of metabolic comorbidities, and, finally, improved ovulation and fertility. This can be achieved with the help of specific agents, particularly metformin and thiazolidinediones. They may ease the suffering of women with PCOS because insulin resistance and hyperinsulinemia appear to be major contributors to the pathophysiology of the syndrome.
AuthorsRenato Pasquali, Alessandra Gambineri
JournalFrontiers of hormone research (Front Horm Res) Vol. 40 Pg. 83-102 ( 2013) ISSN: 1662-3762 [Electronic] Switzerland
PMID24002407 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2013 S. Karger AG, Basel.
Chemical References
  • Insulin
  • PPAR gamma
  • Thiazolidinediones
  • Clomiphene
  • Metformin
  • Animals
  • Clomiphene (administration & dosage)
  • Diabetes Mellitus, Type 2 (prevention & control)
  • Female
  • Humans
  • Hyperandrogenism (drug therapy)
  • Hyperinsulinism (drug therapy)
  • Insulin (metabolism)
  • Insulin Resistance (physiology)
  • Life Style
  • Menstrual Cycle (drug effects)
  • Metformin (pharmacokinetics, therapeutic use)
  • Ovulation (drug effects)
  • PPAR gamma (drug effects)
  • Polycystic Ovary Syndrome (drug therapy, physiopathology)
  • Thiazolidinediones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: